Background {#Sec1}
==========

Colon cancer accounts for more than 1632 deaths per day and has a morality rate of approximately 19.1/100,000, ranking fourth in China and making it the most common malignant digestive tumor \[[@CR1]\]. The incidence of colon cancer and patient overall survival (OS) have continued to increase over the past 3 decades worldwide \[[@CR2]\]. Patients with colon cancer had a 5-year OS rate of 65.2%, which made colon cancer a serious problem for public health.

The prognosis of colon cancer is associated with the American Joint Commission on Cancer/International Union against Cancer (AJCC/UICC) tumor--node--metastasis (TNM) staging system. According to stages defined by the TNM system, the 5-year stage-specific survival rates are 93.2% for stage I, 82.5% for stage II, and 59.5% for stage III \[[@CR3]\]. Nonetheless, patients with stage I--III colon cancer usually have an obviously divergent prognosis because of discrepant genetic and epigenetic backgrounds, even though some colon cancer patients are in the same AJCC stage. Compared with patients with stage IIIa colon cancer, whose 5-year survival rate is 83.4%, patients with stage IIb colon cancer, whose 5-year survival rate is 72.2%, experience severe prognostic events similar to patients with stage IIIb colon cancer, whose 5-year survival rate is 64.1% \[[@CR4]\]. Although the TNM staging system is most widely used for prognosis assessment and medical treatments in colon cancer patients, excessive hidden defects still limit its practical application.

Some studies have described that clinicopathological features such as tumor size, the carcinoembryonic antigen (CEA) level, adjuvant chemotherapy, and the log odds of metastatic lymph nodes (LODDS) may also influence colon cancer patients' survival outcomes \[[@CR5], [@CR6]\]. In addition to clinicopathological features, various nonbiological factors were proposed to be included in the patient's clinical assessment for malignant tumor therapy. For instance, marital status is a significant factor in clinical resolution. Socioeconomic status and insurance status are also important when selecting a treatment strategy. Multiple factors are needed to account for the wide range of variability observed in individual patients. Ignoring these significant prognostic parameters may reduce the accuracy of survival predictions. Thus, a comprehensive prognostic judgment system including clinicopathological and demographic factors is required in clinical practice.

In fact, various prognostic analysis methods have been applied to clinical applications. For instance, microsatellite instability (MSI) or mismatch repair deficiency (dMMR) status is considered the most important biomarker in colon cancer patients \[[@CR7], [@CR8]\]. Chromosomal instability (CIN) and CpG island methylator phenotype (CIMP) are also widely accepted as biomarkers for metastasis risk and prognostic analysis \[[@CR9]\]. In addition, certain genes and molecules, such as the KRAS gene, the APC gene, the p53 gene, CD44, CD133, and MEK, have been found to be indicators for judging the prognosis of colon cancer patients \[[@CR10]--[@CR12]\]. However, these methods of detection and judgment not only sometimes result in trauma to the patient but also have considerable economic costs. As a convenient and saving graphical interface of a statistical prediction model, nomograms in which various significant variables are combined to predict a specific endpoint have been built by scientists to meet this demand. By integrating these clinical and pathological features, a nomogram simplifies the complicated computational model into a single numerical estimation probability, such as death or disease recurrence, which is tailored to the individual condition. Therefore, a nomogram might be used as a dependable instrument for predicting patients' survival outcomes and supporting decisions with regard to surgery, surveillance, and adjuvant treatments. Recently, some researchers have reported that the nomogram scoring system has an exceptional capability in predicting prognosis \[[@CR13], [@CR14]\]. However, most nomograms used to predict the prognosis of patients with colon cancer, of which the sample size used for development was limited, required a combination of molecular biology tests, which increased the economic burden, time and cost for the patient. This research aimed to develop nomograms that require only clinical features combined with the patient's socioeconomic status, which is easy to obtain.

The Surveillance, Epidemiology, and End Results (SEER) program provides a profusion of integral information for different cancers from 20 cancer registries that cover \~ 28% of the population. Based on the SEER database, researchers have conducted several studies on the prognosis of cancer \[[@CR15]\]. In the present research, information on stage I--III colon cancer was collected from the SEER database to build a nomogram that was intuitive and convenient for predicting the prognosis of colon cancer patients.

Methods {#Sec2}
=======

Patients selection {#Sec3}
------------------

In this study, a total of 167,333 patients with colon cancer were acquired from the SEER database. The detailed workflow for patient selection is shown in Fig. [1](#Fig1){ref-type="fig"}. All colon cancer patients treated with radical surgery between January 1, 2010 and December 31, 2015, were assessed for inclusion in the retrospective analysis. Patients were excluded if non-colon cancer was stated in the pathology report, if they were diagnosed with TNM stage IV or an unknown stage cancer and if they suffered from 2 or more malignant tumors. Eighteen variables were extracted from the SEER program in this study, including race, carcinoembryonic antigen (CEA) level, age, year of diagnosis, sex, adjuvant chemotherapy, histological type, grade, tumor size, number of lymph nodes harvested (LNH), regional nodes positive, LODDS stage, marital status, tumor site, tumor deposit, T stage, N stage, and TNM stage. Patients whose races were recorded as Native American, Asian, Pacific Islander and unknown in the SEER database were assigned to the "other" race category for analysis. Patients without any of these 18 variables were excluded. Patient survival was measured as cause-specific survival (CSS) and OS \[[@CR16]\]. Finally, data on 34,432 patients diagnosed with stage I--III colon cancer between 2010 and 2015 were obtained from the SEER database.Fig. 1The workflow of establishment of nomograms to predict cause-specific survival and overall survival of patients with stage I--III colon cancer

Construction and validation of the nomogram {#Sec4}
-------------------------------------------

Univariable and multivariable Cox regression analyses were used to calculate the effect of variables on CSS and OS. The measure of the effect of each variable on CSS and OS is presented as the hazard ratio (HR) and was used to identify independent risk factors. Based on the multivariable Cox regression analyses, two applied nomograms incorporating clinicopathological parameters into the TNM staging system were formulated. The total points in each case of the two survival groups were calculated using the established nomograms, after which Cox regression analysis of the whole cohort was performed using the total points as a parameter. Patients were divided into low- and high-risk groups based on the nomogram risk score and using the median risk score as the cut-off point.

The concordance index (C-index), receiver operating characteristic (ROC) and decision curve analysis (DCA) {#Sec5}
----------------------------------------------------------------------------------------------------------

The distinguishing ability of the nomogram was evaluated by the C-index and ROC curve analysis. The C-index was defined as the ratio of all patient pairs predicted to be consistent with the results. The 1-, 3-, and 5-year ROC curves were used to appraise the nomogram's predictive ability over time. DCA was recently proposed as a fresh method of evaluating predictive models and can be used to visualize the clinical consequences of a treatment method \[[@CR17]\]; thus, DCA was carried out to compare the latent profit of the prognostic nomogram in this study.

Risk stratification based on the novel nomogram {#Sec6}
-----------------------------------------------

To verify the independent discriminatory ability of the nomogram, this research regrouped all patients into high-, moderate-, and low-risk groups according to the total risk scores. Survival curves for different risk groups were generated using the Kaplan--Meier method and were differentiated using the log-rank test.

Statistical analyses {#Sec7}
--------------------

R software (version 3.6.0, <http://www.r-project.org>) was used for all statistical analyses. The R statistical packages "rms", "survival", "Hmisc", "MASS", and "survivalROC" were used to calculate the C-index, plot the calibration and ROC curves, build the nomogram, and draw Kaplan--Meier curves, while the package "rmda" was used to draw the DCA curves. All statistical tests were 2-sided, and p values \< 0.05 were considered statistically significant.

Results {#Sec8}
=======

Patients' clinical characteristics and survival outcomes {#Sec9}
--------------------------------------------------------

Data on a total of 34,432 patients with stage I--III colon cancer were retrospectively collected from the SEER database. The patients' clinicopathological characteristics and 1-, 3-, and 5-year CSS and OS rates are listed in Table [1](#Tab1){ref-type="table"}.Table 1Patient characteristics and 1-, 3-, and 5-year CSS and OS ratesCharacteristicsN%CSSOS1-year (%)3-year (%)5-year (%)1-year (%)3-year (%)5-year (%)Gender Female17,42750.694.587.182.391.781.072.6 Male17,00549.495.588.583.192.081.472.0Race White26,83978.094.988.183.591.681.272.6 Other^a^759322.095.087.182.492.181.471.9Year of diagnosis 2010--201216,26247.294.887.582.691.680.872.0 2013--201518,17052.895.287.984.592.081.676.8Age at diagnosis \< 6010,60230.898.392.887.797.691.185.0 ≥ 6023,83069.293.585.580.589.276.966.8Tumor site Right19,80757.594.386.582.090.878.969.9 Left14,62542.595.989.583.893.284.375.6Histological subtype AD31,23990.795.288.383.392.181.973.0 MAD29038.494.284.880.090.476.668.0 SRCC2900.978.258.551.974.452.744.8Pathologic grade Grade I25857.597.192.389.094.385.978.3 Grade II25,43873.996.089.684.692.983.174.2 Grade III537415.690.579.473.787.172.963.3 Grade IV10353.087.774.168.384.067.458.3T stage T132959.699.097.896.596.592.386.6 T2590117.197.896.093.694.888.781.2 T320,39059.295.588.182.992.381.472.4 T4a31229.188.470.760.084.464.651.4 T4b17245.084.066.656.780.761.450.8N stage N020,99161.096.993.290.193.785.978.0 N1912426.593.983.876.890.878.268.1 N2431712.587.869.759.684.964.753.4Chemotherapy No23,10667.194.088.284.589.879.670.9 Yes11,32632.997.087.079.596.084.375.2LNH \< 12356210.391.982.677.387.273.864.1 ≥ 1230,87089.795.388.483.492.382.173.3LODDS stage LODDS 121,98163.896.992.989.793.685.677.7 LODDS 211,37633.093.181.473.490.276.065.3 LODDS 310092.978.954.244.775.549.039.3 LODDS 4660.346.116.812.043.215.811.3Tumor size \< 413,75740.096.991.687.494.085.276.6 ≥ 420,67560.093.785.279.690.378.569.4CEA Negative22,28964.796.691.487.594.085.777.9 Positive12,14335.392.080.973.787.873.062.0Tumor deposit Negative32,10693.295.388.884.092.282.173.3 Positive23266.890.372.863.286.868.156.6Marriage status Married19,31956.196.490.485.794.085.477.8 Single557616.295.286.480.892.179.970.8 Separated/Divorced376910.995.087.181.592.080.971.7 Widowed576816.889.980.375.284.268.756.2TNM stage I755421.998.497.395.695.690.383.6 II13,43739.096.190.987.092.683.574.9 III13,44139.192.079.371.388.973.963.4*CSS*, cause-specific survival, *OS* overall survival, *AD* adenocarcinoma, *MAD* mucinous adenocarcinoma, *SRCC* signet ring cell carcinoma, *LNH* lymph nodes harvested, *LODDS* log of odds between the number of positive lymph node and the number of negative lymph node, *CEA* carcinoembryonic antigen, *TNM* tumor-node-metastasis^a^Includes Black, Native American, Asian, Pacific Islander and Unknown

In the whole group, most patients were White (26,839; 78%) and older than 60 years (23,830; 69.2%), had the adenocarcinoma histological type (31,239; 90.7%), moderately differentiated tumors (25,438; 73.9%), LNH ≥ 12 (30,870; 89.7%), and LODDS stage 1 (21,981; 63.8%) and were CEA negative (22,289; 64.7%) and tumor deposit negative (32,106; 93.2%). Moreover, 67.1% of patients across the entire study population did not undergo chemotherapy. TNM stage I, II, and III tumors accounted for 21.9%, 39.0%, and 39.1% of all cases, respectively. The 1-, 3-, and 5-year CSS rates were 95.0%, 87.8%, and 82.7% for all patients, respectively, with a mean follow-up time of 72.7 months. The 1-, 3-, and 5-year OS rates were 91.8%, 81.2%, and 72.3% for all patients, respectively, with a mean follow-up time of 66.4 months.

Independent prognostic factors in stage I--III colon cancer patients {#Sec10}
--------------------------------------------------------------------

According to the results based on the univariate Cox regression analysis, 13 variables, namely, sex, age at diagnosis, primary tumor site, histological type, pathological grade, adjuvant chemotherapy, LNH, LODDS stage, tumor size, CEA level, marital status, T stage, and N stage, were associated with CSS and OS (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}). In the multivariate Cox regression analysis, twelve parameters, namely, age at diagnosis, primary tumor site, histological type, pathological grade, adjuvant chemotherapy, LNH, LODDS stage, tumor size, CEA level, marital status, T stage, and N stage, were defined as independent prognostic factors predicting the CSS of stage I--III colon cancer patients (Table [2](#Tab2){ref-type="table"}). All thirteen comparable variables (i.e., sex, age at diagnosis, primary tumor site, histological type, pathological grade, adjuvant chemotherapy, LNH, LODDS stage, tumor size, CEA level, marital status, T stage, and N stage) were defined as independent prognostic factors predicting the OS of stage I--III colon cancer patients (Table [3](#Tab3){ref-type="table"}).Table 2Univariable and multivariable Cox regression model analyses of cause-specific survival in nomogram cohortVariableUnivariable analysisMultivariable analysisHR95% CIP-valueHR95% CIP-valueGender0.0020.066 Female11 Male0.9090.857--0.9651.0580.965--1.054Race0.985 White1 Other^a^1.0010.907--1.105Year of diagnosis0.445 2010--20121 2013--20150.9760.915--1.040Age at diagnosis\< 0.001\< 0.001 \< 6011 ≥ 601.9131.781--2.0561.7181.591--1.856Tumor site\< 0.0010.003 Right11 Left0.8250.778--0.8750.9120.857--0.970Histological subtype\< 0.0010.001 AD11 MAD1.2511.135--1.378\< 0.0010.9830.891--1.0850.738 SRCC4.0423.368--4.851\< 0.0011.4441.195--1.746\< 0.001Pathological grade\< 0.001\< 0.001 Grade I11 Grade II1.4471.259--1.664\< 0.0011.0800.939--1.2430.282 Grade III2.8672.477--3.319\< 0.0011.3501.162--1.568\< 0.001 Grade IV3.7043.091--4.439\< 0.0011.6501.372--1.984\< 0.001T stage\< 0.001\< 0.001 T111 T22.0221.590--2.573\< 0.0011.7411.366--2.218\< 0.001 T35.4974.429--6.822\< 0.0013.5792.864--4.472\< 0.001 T4a14.59411.686--18.226\< 0.0017.2835.775--9.186\< 0.001 T4b17.47913.929--21.933\< 0.0019.4777.467--12.029\< 0.001N stage\< 0.001\< 0.001 N011 N12.4182.257--2.591\< 0.0012.0901.774--2.461\< 0.001 N24.6794.437--5.125\< 0.0013.2202.678--3.872\< 0.001Chemotherapy\< 0.001\< 0.001 No11 Yes1.1421.076--1.2130.4980.465--0.534LNH\< 0.001\< 0.001 \< 1211 ≥ 120.6690.617--0.7260.5820.535--0.634LODDS stage\< 0.001\< 0.001 LODDS 111 LODDS 22.6892.528--2.861\< 0.0011.2901.097--1.5170.002 LODDS 37.3596.64--8.156\< 0.0012.0051.647--2.442\< 0.001 LODDS 421.94816.814--28.649\< 0.0014.2743.109--5.876\< 0.001Tumor size\< 0.0010.038 \< 411 ≥ 41.7811.671--1.8991.0751.004--1.152CEA\< 0.001\< 0.001 Negative11 Positive2.2922.163--2.4291.5751.484--1.671Marriage status\< 0.001\< 0.001 Married11 Single1.3231.199--1.459\< 0.0011.1971.085--1.321\< 0.001 Separated/Divorced1.3971.285--1.519\< 0.0011.2981.193--1.493\< 0.001 Widowed2.0841.937--2.243\< 0.0011.4701.362--1.587\< 0.001*HR* hazard ratio, *CI* confidence interval, *AD* adenocarcinoma, *MAD* mucinous adenocarcinoma, *SRCC* signet ring cell carcinoma, *LNH* lymph nodes harvested, *LODDS* log of odds between the number of positive lymph node and the number of negative lymph node, *CEA* carcinoembryonic antigen, *TNM* tumor-node-metastasis^a^Includes Black, Native American, Asian, Pacific Islander and Unknown Table 3Univariable and multivariable Cox regression model analyses of overall survival in nomogram cohortVariableUnivariable analysisMultivariable analysisHR95% CIP-valueHR95% CIP-valueGender0.0170.001 Female11 Male1.0051.002--1.0361.2481.190--1.309Race0.097 White1 Other^a^0.9700.935--1.006Year of diagnosis0.082 2010--20121 2013--20150.9570.910--1.006Age at diagnosis\< 0.001\< 0.001 \< 6011 ≥ 602.7242.560--2.8992.2282.086--2.379Tumor site\< 0.001\< 0.001 Right11 Left0.7530.719--0.7890.8650.825--0.908Histological subtype\< 0.0010.001 AD11 MAD1.2601.170--1.358\< 0.0011.0240.949--1.1040.540 SRCC2.9472.500--3.474\< 0.0011.4031.184--1.663\< 0.001Pathologic grade\< 0.001\< 0.001 Grade I11 Grade II1.1991.090--1.320\< 0.0011.0290.934--1.1340.557 Grade III1.9231.734--2.134\< 0.0011.2061.083--1.3420.001 Grade IV2.3712.064--2.724\< 0.0011.4181.231--1.634\< 0.001T stage\< 0.001\< 0.001 T111 T21.4621.292--1.654\< 0.0011.3171.162--1.493\< 0.001 T32.2682.034--2.528\< 0.0011.7691.576--1.987\< 0.001 T4a4.6714.146--5.262\< 0.0013.1142.737--3.543\< 0.001 T4b5.1104.498--5.806\< 0.0013.6343.163--4.175\< 0.001N stage\< 0.001\< 0.001 N011 N11.5331.456--1.615\< 0.0011.6461.444--1.876\< 0.001 N22.5572.413--2.709\< 0.0012.3642.035--2.746\< 0.001Chemotherapy\< 0.001\< 0.001 No11 Yes0.7330.697--0.7710.4290.404--0.455LNH\< 0.001\< 0.001 \< 1211 ≥ 120.6740.633--0.7170.6210.581--0.663LODDS stage\< 0.001\< 0.001 LODDS 111 LODDS 21.6741.598--1.754\< 0.0011.2471.093--1.4230.001 LODDS 33.9413.602--4.312\< 0.0011.8531.570--2.188\< 0.001 LODDS 410.5628.166--13.662\< 0.0013.5922.674--4.825\< 0.001Tumor size\< 0.0010.048 \< 411 ≥ 41.4461.379--1.5171.0501.004--1.102CEA\< 0.001\< 0.001 Negative11 Positive1.9431.858--2.0321.5151.446--1.587Marriage status\< 0.001\< 0.001 Married11 Single1.3181.220--1.423\< 0.0011.2661.171--1.367\< 0.001 Separated/divorced1.3661.279--1.460\< 0.0011.3941.304--1.491\< 0.001 Widowed2.3752.248--2.510\< 0.0011.7561.654--1.865\< 0.001*HR* hazard ratio, *CI* confidence interval, *AD* adenocarcinoma, *MAD* mucinous adenocarcinoma, *SRCC* signet ring cell carcinoma, *LNH* lymph nodes harvested, *LODDS* log of odds between the number of positive lymph node and the number of negative lymph node, *CEA* carcinoembryonic antigen, *TNM* tumor-node-metastasis^a^Includes Native American, Asian, Pacific Islander and Unknown

Construction and validation of the prognostic prediction nomogram {#Sec11}
-----------------------------------------------------------------

Considering the results of the multivariable Cox regression analysis for CSS and OS, all of the significant variables were used to create the nomogram for CSS and OS. The prognostic nomogram for 1-, 3-, and 5-year CSS is shown in Fig. [2](#Fig2){ref-type="fig"}. The prognostic nomogram for 1-, 3-, and 5-year OS is shown in Fig. [3](#Fig3){ref-type="fig"}. By summing the scores associated with each variable and projecting total scores to the bottom scale, the probabilities can be estimated for 1-, 3-, and 5-year CSS and OS.Fig. 2Nomogram convey the results of prognostic models using twelve clinicopathological characteristics to predict cause-specific survival of patients with stage I--III colon cancer Fig. 3Nomogram convey the results of prognostic models using thirteen clinicopathological characteristics to predict overall survival of patients with stage I--III colon cancer

C-index values and ROC curves are ordinarily used to evaluate the discriminatory power of a nomogram. The C-indexes for the prediction of CSS and OS were 0.78 (95% CI 0.77--0.80) and 0.74 (95% confidence interval (CI) 0.73--0.75), respectively. To confirm that the nomogram had higher efficacy in predicting the prognosis of stage I--III colon cancer patients than TNM stage, time-dependent ROC analyses at 1, 3, and 5 years were conducted. The 1-, 3-, and 5-year AUC values of the nomogram for the prediction of CSS were 0.81, 0.807, and 0.787, respectively, compared with 0.646, 0.680, and 0.683, respectively, for the AUC values of TNM stage (Fig. [4](#Fig4){ref-type="fig"}a--c). In addition, the 1-, 3-, and 5-year AUC values of the nomogram for the prediction of OS were 0.782, 0.76, and 0.741, respectively, compared with 0.592, 0.613, and 0.606, respectively, for the AUC values of TNM stage (Fig. [4](#Fig4){ref-type="fig"}d--f). In addition, calibration curves for the nomogram showed no deviations from the reference line, which indicating a high degree of credibility (Fig. [5](#Fig5){ref-type="fig"}a--f).Fig. 4**a** AUC values of ROC predicted 1-year cause-specific survival rates of Nomogram and TNM stage. **b** AUC values of ROC predicted 3-year cause-specific survival rates of Nomogram and TNM stage. **c** AUC values of ROC predicted 5-year cause-specific survival rates of Nomogram and TNM stage. **d** AUC values of ROC predicted 1-year overall survival rates of Nomogram and TNM stage. **e** AUC values of ROC predicted 3-year overall survival rates of Nomogram and TNM stage. **f** AUC values of ROC predicted 5-year overall survival rates of Nomogram and TNM stage Fig. 5**a** The calibration curve for predicting patients' cause-specific survival at 1-year. **b** The calibration curve for predicting patients' cause-specific survival at 3-year. **c** The calibration curve for predicting patients' cause-specific survival at 5-year. **d** The calibration curve for predicting patients' overall survival at 1-year. **e** The calibration curve for predicting patients' overall survival at 3-year. **f** The calibration curve for predicting patients' overall survival at 5-year

The clinically and statistically significant prognostic performance of the nomogram based on the entire group of patients and risk scores was validated by a stratified analysis, which suggested that the nomogram could be used to clinically and statistically predict the prognosis of patients with stage II (Fig. [6](#Fig6){ref-type="fig"}a, b), and stage II--III colon cancer with or without adjuvant chemotherapy (Fig. [6](#Fig6){ref-type="fig"}e--h).Fig. 6**a** Kaplan--Meier estimated cause-specific survival in patients with TNM stage II colon cancer stratified by the nomogram risk score. **b** Kaplan--Meier estimated overall survival in patients with TNM stage II colon cancer stratified by the nomogram risk score. **c** Kaplan--Meier estimated cause-specific survival in patients with TNM stage III colon cancer stratified by the nomogram risk score. **d** Kaplan--Meier estimated overall survival in patients with TNM stage III colon cancer stratified by the nomogram risk score. **e** Kaplan--Meier estimated cause-specific survival in stage II--III colon cancer patients without chemotherapy stratified by the nomogram risk score. **f** Kaplan--Meier estimated overall survival in stage II--III colon cancer patients without chemotherapy stratified by the nomogram risk score. **g** Kaplan--Meier estimated cause-specific survival in stage II--III colon cancer patients with chemotherapy stratified by the nomogram risk score. **h** Kaplan--Meier estimated overall survival in stage II--III colon cancer patients with chemotherapy stratified by the nomogram risk score

Clinical value of the nomogram {#Sec12}
------------------------------

DCA is a novel method used to evaluate alternative prognostic strategies and has advantages over the AUC. DCA curves for the novel nomogram and TNM stage are presented in Fig. [7](#Fig7){ref-type="fig"}. Compared with the TNM staging system, the DCA of the nomogram has higher net benefits, indicating that it has better clinical application value than TNM stage.Fig. 7**a** Decision curve analysis of the nomogram and TNM stage for the cause-specific survival prediction of stage I--III colon cancer patients. **b** Decision curve analysis of the nomogram and TNM stage for the overall survival prediction of stage I--III colon cancer patients

Prognostic nomogram for risk stratification {#Sec13}
-------------------------------------------

By regrouping all patients in the CSS and OS cohorts into three subgroups based on the total scores, the cut-off values were defined, and each group represents a distinct prognosis. The Kaplan--Meier survival curves were subsequently delineated and are shown in Fig. [8](#Fig8){ref-type="fig"}. In the CSS cohort, Group 1 (low-risk group) had the highest 5-year CSS rate of 95.0%, followed by Group 2 (moderate-risk group; 88.6%) and Group 3 (high-risk group 64.0%). In the OS cohort, Group 1 (low-risk group) had the highest 5-year OS rate of 89.1%, followed by Group 2 (moderate-risk group 76.8%) and Group 3 (high-risk group 51.5%). A significant statistical distinction in survival outcomes was observed between the three groups.Fig. 8**a** Cause-specific survival in the subgroups according to a tertiles of the total score. **b** Overall survival in the subgroups according to a tertiles of the total score

Discussion {#Sec14}
==========

Through this study, a nomogram merging clinicopathological parameters with the TNM staging system was built to assess the definite 1-, 3-, and 5-year CSS and OS probabilities of stage I--III colon cancer patients. The behavior of the nomogram (i.e., discrimination and calibration) was verified. From the perspective of clinical influence, the nomogram had a wide range of threshold probabilities. From the perspective of ROC curve analysis and DCA, the nomogram showed better predictive accuracy and prognostic value in stage I--III colon cancer compared to the current TNM staging system. Moreover, the nomogram was competent to divide patients with stage I--III colon cancer into low-, moderate-, and high-risk groups, which indicates that the nomogram can be utilized as a conventional equipment in predicting the prognosis of stage I--III colon cancer.

In the present study, it was found that the number of young individuals diagnosed with colon cancer has increased. Previous research has revealed that age is an independent prognostic factor of stage I--III colon cancer patients, with a younger age indicating more pronounced outcomes \[[@CR6]\]. In addition, a considerable prognostic factor certified by this study was CEA, which is a well-established biomarker for colon cancer recommended by both the American Society of Clinical Oncology (ASCO) and the European Group on Tumor Markers (EGTM) \[[@CR18]--[@CR20]\]. Preoperative CEA levels were used to predict prognosis, and routine CEA monitoring during the postoperative follow-up was used to monitor local relapse and distant metastases after colon cancer surgery. As this nomogram showed, stage I--III colon cancer patients with high CEA levels tended to have significantly poor CSS and OS rates. In addition, left-sided colon cancers (LCCs) and right-sided colon cancers (RCCs) are thought to have different embryological origins \[[@CR21]\]. Various differences, such as anatomical structure, function, morphological characteristics, and histochemical reactions, exist between the two. Patients with LCC have a significantly better prognosis than those with RCC in terms of OS, which was indicated by this research. In addition, tumor size \[[@CR5]\] was validated as an independent factor for OS in patients with colorectal adenocarcinoma of infiltrative and ulcerative types in a previous study. This research suggested that large tumors led to a poor prognosis.

Whether adjuvant chemotherapy is suitable for stage I--III colon cancer remains controversial. According to the NCCN guidelines, it is recommended that patients with stage II colon cancers with risk factors and stage III colon cancers accept adjuvant chemotherapy \[[@CR22], [@CR23]\]. In this study, histological differentiation, grade, right colon, LNH less than 12, LODDS, tumor size, marital status, T stage, and N stage were identified as independent risk factors for stage I--III colon cancer \[[@CR14]\]. Histological differentiation was identified as an important feature to evaluate the benefit of adjuvant chemotherapy in a previous study \[[@CR24]\]. This nomogram proved that low histological differentiation was associated with a poor prognosis. Low histological grade was considered among the adverse histopathological factors associated with an unfavorable clinical course of colon cancer. A previous study demonstrated that tumor location was associated with prognosis in colon cancer patients \[[@CR21]\]. Furthermore, the appropriate staging of colon cancer requires at least 12 lymph nodes to be sampled, as recommended by the NCCN guidelines. Relevant research indicated that stage I--III colon cancer patients with LNH less than 12 tended to have shorter CSS and OS than those with LNH more than 12, which corroborated the results of this nomogram \[[@CR25]\].

Some scholars have trusted that the LODDS is a more accurate method for predicting the prognosis of patients with colon cancer after an operation than the N stage. The LODDS was defined as follows: log((number of positive lymph nodes + 0.05)/(number of negative nodes + 0.05)). The LODDS range in this research was − 3.256 to 2.858. The LODDS system was divided into four levels to determine the LODDS status: LODDS1 (LODDS ≤ − 1.5), LODDS2 (− 1.5 ≤ LODDS \< 0), LODDS3 (0 ≤ LODDS \< 1.5), and LODDS4 (LODDS ≥ 1.5) \[[@CR26], [@CR27]\]. This nomogram showed that a high LODDS status was related to poor survival outcomes.

Marital status is another independent prognostic factor for survival in colon cancer. Previous research showed that being married was associated with better outcomes of colon cancer patients, but unmarried colon cancer patients, including single, separated, divorced, and widowed patients, were at a greater risk of mortality \[[@CR15]\], which was reproduced in this research. Our nomogram shows that separated, divorced, and widowed patients were associated with a greater risk of mortality.

However, this study still had some limitations. First, treatment information except for surgery was not available in the SEER database and was thus not incorporated into our analysis. Second, the SEER database is devoid of variables such as detailed histological information, mode of presentation, and ECOG prognostic scores and lacks 90% of biomarker expression states (e.g., RAS, BRAF, PIK3CA and genes involved in DNA mismatch repair, which have been proven to predict survival). Last, this study did not contain any external validation cohort. Additional prospective data and the incorporation of other factors are encouraged to improve this model.

Conclusion {#Sec15}
==========

In conclusion, we established and validated a nomogram for predicting CSS and OS probabilities in stage I--III colon cancer patients. The simple nomogram had sufficient discriminatory and calibration capability in addition to exceptional clinical effectiveness and could be an easy-to-use tool for clinicians to promote a personalized postoperative prognostic assessment and to identify treatment strategies for patients with stage I--III colon cancer.
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